ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (USA)
WISCONSIN ALUMNI RESEARCH FOUNDATION (USA)
UNIVERSITY OF ARIZONA (USA)
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventeur(s)
Chakrabarti, Chaitali
Ogras, Umit
Goksoy, Ahmet
Krishnakumar, Anish
Akoglu, Ali
Hassan, Md Sahil
Marculescu, Radu
Farcas, Allen-Jasmin
Abrégé
Provided herein are dynamic adaptive scheduling (DAS) systems. In some embodiments, the DAS systems include a first scheduler, a second scheduler that is slower than the first scheduler, and a runtime preselection classifier that is operably connected to the first scheduler and the second scheduler, which runtime preselection classifier is configured to effect selective use of the first scheduler or the second scheduler to perform a given scheduling task. Related systems, computer readable media, and additional methods are also provided.
A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
3.
TUMOR TARGETED FLUORESCENCE GUIDANCE FOR INTRAOPERATIVE MARGIN ASSESSMENT
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
4.
METHODS AND SYSTEMS FOR IMPLANTABLE MEDICAL DEVICES AND VASCULARIZATION MEMBRANES
An implantable medical device and methods for making and using the same are provided. In various embodiments, the device comprises a central hub structure in communication with at least one housing or pod capable of containing cells and therapeutic materials. Also provided are membrane structures and methods of forming the same, the membranes comprising a gradient of varying porosity for use with devices of the present disclosure, as well as other uses.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61L 27/00 - Matériaux pour prothèses ou pour revêtement de prothèses
5.
METHODS FOR TREATING OR LIMITING DEVELOPMENT OF CARDIOVASCULAR DISEASE-RELATED NEUROLOGICAL DISORDERS
Disclosed herein are methods for treating or limiting development of cardiovascular disease-related neurological disorders by administering a compound of general formula (I), as defined herein.
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
C07D 213/44 - Radicaux substitués par des atomes d'oxygène, de soufre ou d'azote liés par des liaisons doubles ou par deux de ces atomes liés au même atome de carbone par des liaisons simples
C07D 417/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
Systems and methods for assessing multi-layer structures in which a spectrum array is generated from low coherence interferometry and input into a statistical estimator, which determines the thickness and layer number based on the inputted spectrum and other information, including information about a source intensity noise, Poisson noise, and dark noise associated with the low coherence interferometry.
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
A61B 3/00 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux
A61B 3/113 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour déterminer ou enregistrer le mouvement de l'œil
7.
CONJUGATES FOR DETECTION OF AXILLARY LYMPH NODE METASTASES
H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (USA)
UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Morse, David L.
Mash, Eugene A.
Abrégé
Disclosed are anti-cancer compounds and imaging agents. More specifically, the disclosed agents target carbonic anhydrase IX and XII and their use in the treatment of cancer, in particular breast cancer. Specific compounds are those that have Formula I I wherein R1 and R2 are each independently chosen from (CH2)nC≡CH and, L is a linking moiety; n is 1-8; m is 0-8; each X is independently chosen from R3, OR3, NH2, NHR3, and; and each R3 is independently chosen from a detectable moiety or targeting moiety, with the proviso that R1 and R2 are not both (CH2)4C≡CH.
C07H 15/04 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide
C07H 15/10 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'oxygène d'un radical saccharide contenant des liaisons non saturées carbone-carbone
C07H 15/26 - Radicaux acycliques ou carbocycliques substitués par des hétérocycles
The Board of Trustees of the Leland Stanford Junior University (USA)
University of Arizona (USA)
Inventeur(s)
Cheng, Yao-Te
Hesselink, Lambertus
Kim, Young-Sik
Takashima, Yuzuru
Yuen, Max
Abrégé
An X-ray detector array includes a scintillator that converts input X-ray radiation to secondary optical radiation output from the scintillator, a first telecentric micro lens array that array receives the secondary optical radiation, a phase coded aperture, where the first telecentric micro lens array directs the secondary optical radiation on the phase coded aperture, a second telecentric micro lens array, where the secondary optical radiation output from the phase coded array is directed to the second telecentric micro lens array, a patterned grating mask, where the second telecentric micro lens array directs the optical beam on the patterned mask, and a photodetector array, where the patterned mask outputs the optical beam in a pattern according to the patterned mask to the photodetector array, where the photodetector array outputs a signal, where a photon fringe pattern is imaged and sampled in the wavelength domain of the radiation from the scintillator.
G01T 1/20 - Mesure de l'intensité de radiation avec des détecteurs à scintillation
G01T 1/202 - Mesure de l'intensité de radiation avec des détecteurs à scintillation le détecteur étant du cristal
G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
9.
AUTOMATED SCIENTIFICALLY CONTROLLED SCREENING SYSTEMS (ASCSS)
The ability to detect when a person is hiding important information has high value in many applications. A new class of systems, termed autonomous scientifically controlled screening systems (ASCSS), is designed to detect individuals' purposely hidden information about target topics of interest. ASCSS represents a systematic synthesis of structured interviewing, orienting theory, defensive response theory, non-invasive psychophysiological measurement, and behavioral measurement. To evaluate and enhance the design principles, an automated screening kiosk (ASK) system was constructed. The ASK system has been used in a physical security screening scenario in which participants constructed and attempted to smuggle a fake improvised explosive device (IED). The ASK system results indicate that ASCSS enables more widespread application of credibility assessment screening systems.
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Lancaster, Jordan J.
Goldman, Steven
Abrégé
Disclosed herein are contractile cell constructs comprising contractile cells, or progenitors thereof, adhered to a surface of a three dimensional fibroblast containing scaffold (3DFCS) and methods for using them to treat disease. In one aspect, the present invention provides methods for preparing a contractile construct, comprising (a) seeding immature contractile cells onto the surface of a three dimensional fibroblast containing scaffold (3DFCS) to produce a contractile construct; and (b) culturing the contractile construct under conditions to promote differentiation of the immature contractile cells into mature contractile cells, wherein the mature contractile cells form striations. In a further aspect, the invention provides methods for treating a disorder characterized by a lack of functioning contractile cells, comprising contacting a patient with a contractile cell-based disorder with an amount effective to treat the disorder with the construct of any embodiment or combination of embodiments of the invention.
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
C12N 11/02 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
Lancaster, Jordan, J.
Goldman, Steven
Abrégé
Disclosed herein are contractile cell constructs comprising contractile cells, or progenitors thereof, adhered to a surface of a three dimensional fibroblast containing scaffold (3DFCS) and methods for using them to treat disease. In one aspect, the present invention provides methods for preparing a contractile construct, comprising (a) seeding immature contractile cells onto the surface of a three dimensional fibroblast containing scaffold (3DFCS) to produce a contractile construct; and (b) culturing the contractile construct under conditions to promote differentiation of the immature contractile cells into mature contractile cells, wherein the mature contractile cells form striations. In a further aspect, the invention provides methods for treating a disorder characterized by a lack of functioning contractile cells, comprising contacting a patient with a contractile cell-based disorder with an amount effective to treat the disorder with the construct of any embodiment or combination of embodiments of the invention.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A tiled head-mounted display device comprises an optical component including a plurality of prisms with free-form surfaces, and a display component including a plurality of micro-displays (6), wherein the number of the micro-displays (6) and the number of the prisms with free-form surfaces is identical, and each prism with free-form surfaces and the corresponding micro-display (6) constitute a display channel. Each prism is a wedge prism including a first surface (2), a second surface (3) and a third surface (4). The exit pupil planes of each display channel are coincident, thus avoiding pupil aberration and keeping exit pupil diameter and eye clearance same as a single ocular. There is no resolution variance throughout the entire field of view, thus preventing extra trapezoid distortion. The tiled head-mounted display device is compact and lightweight, and provides wide field of view and high resolution. The tiled head-mounted display device can be readily applicable to augmented environments applications by simply adding an auxiliary free-form lens behind the prism with free-form surfaces.
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) (USA)
Inventeur(s)
Dorr, Robert
Flynn, Gary
Han, Haiyong
Hurley, Laurence
Abrégé
A 2-aryl-pyridylazole compound and derivatives useful in slowing the growth of cancer cells are disclosed. Also disclosed are methods of synthesizing the compound, methods of using pharmaceutical compositions containing the compound as an ingredient to slow the growth of cancer cells, and methods of treating cancer patients with pharmaceutical compositions containing the compound as an ingredient.
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (France)
UNIVERSITY OF ARIZONA (USA)
Inventeur(s)
Placko, Dominique
Liebeaux, Nicolas
Cruau, Aurélie
Kundu, Tribikram
Abrégé
The invention concerns a method for modeling interactions between at least one wave and at least one object, the surface of each object defining an interface between at least two media. The invention is characterized in that said method includes essentially the following steps: selecting the set of elementary characteristic functions corresponding to the field of application concerned (E1), defining the physical properties of each medium concerned constituting the system (E2), creating each object of the system by meshing same and associating with each mesh at least one punctual elementary source, determining the type of conditions at the boundaries for each interface, constructing the global matrix between the different objects, based on the conditions at the boundaries, inverting the global matrix, multiplying the inverted matrix by a column matrix containing the values of the conditions at the boundaries, obtaining a column matrix containing the values of the set of elementary punctual sources, computing in every point of the system the physical quantities representing interactions between and obtaining an analytical model of the interactions within the system.
Compositions and methods useful for increasing GST-pi expression and/or GST-pi activity in human penpheral blood cells by administering daily in an oral dosage a green tea polyphenol composition consisting of epigallocatechin gallate, epigallocathechin, epicatechin, epicatechin gallate, gallocatechin gallate and/or polyphenon E.
C12N 9/00 - Enzymes, p. ex. ligases (6.)ProenzymesCompositions les contenantProcédés pour préparer, activer, inhiber, séparer ou purifier des enzymes
A61K 31/35 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle
16.
METHODS, COMPOUNDS AND COMPOSITIONS WITH GENOTYPE SELECTIVE ANTICANCER ACTIVITY
This invention is directed to methods for screening and identification of compounds capable of selectively eliminating cancer cells with specific loss-of- function alterations, including but not limited to mutations, deletions, hypermethylations, and other types of gene silencing. This invention is also directed to novel compounds that selectively eliminate cancer cells with specific loss-of-f unction alterations. Furthermore, this invention is directed to methods for production and therapeutic use of compounds that selectively eliminate cancer cells with specific loss-of-function alterations.
C04B 20/00 - Emploi de matières comme charges pour mortiers, béton ou pierre artificielle prévu dans plus d'un groupe et caractérisées par la forme ou la répartition des grainsTraitement de matières spécialement adapté pour renforcer leur propriétés de charge dans les mortiers, béton ou pierre artificielle prévu dans plus d'un groupe de Matières expansées ou défibrillées
17.
THERAPEUTIC PEPTIDES FOR THE TREATMENT OF METASTATIC CANCER
Interaction between MUCl and &bgr;-catenin can be interrupted using polypeptides or antibodies that specifically bind to the binding site on MUCl. Interruption provides the beneficial effect of inhibiting, reducing, and/or retarding invasiveness and metastasis. Fusion polypeptides and antibodies are provided to achieve a therapeutic effect.
Anti-CEACAM6 antibodies and antibody fragments, nucleic acids encoding them, methods of their manufacture, and methods to treat cancer using these compounds are provided.
